BOOG SABCS avond 14-12-2021
Ook dit jaar hebben wij de traditie voortgezet en een SABCS avond georganiseerd in het kader van het San Antonio Breast Cancer Symposium (SABCS). Dit jaar weer in een digitale variant en enkele dagen na SABCS. Deze avond is gehouden op 14 december 2021
Highlights van Nederlandse bodem en onze sponsoren
18:15-18:30 uur |
Inloggen ZOOM |
|
|
18:30-18:35 uur |
Welkom (dr. Agnes Jager, EMC, voorzitter BOOG) |
|
|
18:35-18:45 uur |
Effect of pertuzumab plus neoadjuvant trastuzumab-based chemotherapy in early-stage HER2-positive breast cancer according to BluePrint molecularly defined breast cancer subtypes (PD15-07) |
|
Anna van der Voort, NKI-AVL |
|
|
18:45-18:55 uur |
Clinicopathological characterization of inflammatory breast cancer in the Netherlands: First results of the prospective INFLAME registry (P1-24-03) |
|
Jasper van Geel, UMCG |
|
|
18:55-19:05 uur |
Towards a new standard for staging: A comparative study of [18F]FES PET/CT vs [18F]FDG PET/CT in patients with clinical stage II/III and locoregional recurrent estrogen receptor positive breast cancer (P3-02-11) |
|
Ramsha Iqbal, Amsterdam UMC – location VUmc
|
|
|
19:05-19:15 uur |
Surgical outcomes of lobular carcinoma in situ diagnosed on core biopsy in Dutch women between 2011 and 2020 (P1-22-07) |
|
Crystal Kerkhoven, CMAnalyzing, Zevenaar |
|
|
19:15-19.25 uur |
Prognosis of pregnancy-associated breast cancer: Inferior outcome in patients diagnosed during second and third gestational trimesters and lactation (P3-12-06) |
|
Carsten Bakhuis, UMC Utrecht |
|
|
19:25-19:35 uur |
10 min. Bio-break |
|
|
19:35-19.45 uur |
The risk for locoregional breast cancer recurrences: significant differences in perceptions among Health Care Professionals (HCPs) |
|
Jet Ankersmid, Santeon Hospital Group, Utrecht |
|
|
19:45-19.55 uur |
Socioeconomic status in young breast cancer patients is associated with inequalities in recurrence patterns: A population-based study in the Netherlands (P3-12-10) |
|
Marissa van Maaren, Netherlands Comprehensive Cancer Organisation (IKNL) |
|
|
19:55-20:15 uur |
Impact of the COVID-19 outbreak on the diagnosis and treatment strategy of Dutch breast cancer patients (P3-12-09, P3-12-29, P3-12-37) |
|
Anouk Eijkelboom, Netherlands Comprehensive Cancer Organisation (IKNL) |
|
|
20:15 uur |
Afsluiting (prof.dr. Lenny Verkooijen, UMCU)
|
|
|
30 min |
‘Greet-and-meet’ via Spatial chat: ontmoet de jonge onderzoekers en elkaar! |
Deze avond is mede mogelijk gemaakt door:
Agendia, AstraZeneca, Daiichi Sankyo, Exact Sciences, Eisai, Gilead, GlaxoSmithKline, Lilly Nederland, Merck Sharp& Dohme,
Nordic Pharma, Roche, SeaGen